Entera Bio to Share Promising Phase 2 Results at NAMS 2025
Entera Bio to Present at NAMS 2025 Annual Meeting
Entera Bio Ltd. (NASDAQ: ENTX), known for its groundbreaking oral peptide and protein replacement therapies, will showcase new clinical data from its Phase 2 trial of EB613 at the upcoming North American Menopause Society (NAMS) Annual Meeting in October 2025. This marks a significant moment as it is Entera's debut presentation at this prestigious event.
Significance of the Presentation
The presentation will highlight findings from the Phase 2 trial, which focuses on early postmenopausal women who face low bone mass or osteoporosis. The study emphasizes the importance of evaluating bone mineral density outcomes over a six-month period. This research zeroes in on a demographic at heightened risk for osteoporosis, a stage where access to effective treatment is crucial yet often inadequate.
Expert Insights
Miranda Toledano, Chief Executive Officer of Entera, stated, "Anabolic therapies have shown a profound ability to rebuild bone, but their widespread use has been limited as they are typically delivered via injections. EB613 introduces the first oral anabolic tablet, which has the potential to facilitate earlier interventions in treatment and widen access for the over 200 million women suffering from osteoporosis globally. The insights we present at NAMS will address a critical question about timely treatment in postmenopausal women."
Details of the Presentation
The specifics of the presentation at NAMS are as follows:
- Conference: North American Menopause Society (NAMS) 2025 Annual Meeting
- Title: EB613 (Oral PTH[1-34] Tablets) Increases BMD Over 6 Months in Early Postmenopausal Women with Low Bone Mass or Osteoporosis: A Phase 2 Randomized Trial
- Presentation Number: P-66
- Session Title: Poster Presentation
- Session Date/Time: Thursday, October 23, 2025, 06:15 PM - 07:15 PM
- Venue: Windemere Exhibit Hall
About EB613
EB613 has demonstrated considerable effectiveness compared to traditional anti-resorptive medications in reducing fracture risk among osteoporosis patients. Importantly, while all current anabolic therapies require injections, entering the market as the first oral option could revolutionize treatment accessibility. EB613’s Phase 2 trial, featuring 161 participants, successfully met all critical endpoints relating to biomarker changes and bone mineral density without notable safety issues in women diagnosed with postmenopausal osteoporosis or low bone density. The results indicate significant increases in biochemical markers of bone formation, alongside reductions in markers indicative of bone loss within the study group.
About Entera Bio
Entera Bio focuses on advancing oral replacement therapies tailored for significant medical needs, employing its proprietary N-Tab™ technology. The company is spearheading innovations in the realm of osteoporosis, with its flagship product, EB613, aimed at becoming the first oral osteoanabolic therapy for postmenopausal women encountering low BMD and osteoporosis. They've conducted successful Phase 2 studies confirming primary and secondary endpoints for EB613. Furthermore, Entera’s pipeline includes an oral PTH(1-34) for a range of conditions affecting calcium levels, as well as therapies intended for metabolic syndromes and malabsorption issues, highlighting the company’s innovative approach to existing medical challenges.
Contact Information
For more details, Ms. Miranda Toledano, Chief Executive Officer of Entera Bio, is available for inquiries. She can be reached via email at miranda@enterabio.com.
Frequently Asked Questions
What is EB613?
EB613 is an oral anabolic tablet therapy developed by Entera Bio for treating osteoporosis in postmenopausal women.
What are the benefits of oral therapies like EB613?
Oral therapies can provide patients with easier access to treatment options compared to injectable medications.
When is Entera Bio presenting EB613 data?
Entera Bio will present at the NAMS 2025 Annual Meeting from October 21-25, 2025.
Who can benefit from EB613?
Women who are postmenopausal and have low bone mass or osteoporosis can benefit from EB613.
Where can I find more information about Entera Bio?
Visit their official website at www.enterabio.com.
About The Author
Contact Caleb Price privately here. Or send an email with ATTN: Caleb Price as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.